Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

스테로이드 저항성 신증후군에서 cyclosporine 치료 반응 및 결과

Therapeutic response of cyclosporine and outcome in steroid resistant nephrotic syndrome

  • 최형순 (울산대학교 의과대학 서울아산병원 소아과학교실) ;
  • 이주훈 (울산대학교 의과대학 서울아산병원 소아과학교실) ;
  • 박영서 (울산대학교 의과대학 서울아산병원 소아과학교실)
  • Choi, Hyung Soon (Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Joo Hoon (Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Young Seo (Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2007.09.18
  • 심사 : 2007.10.22
  • 발행 : 2008.03.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적 : 스테로이드 저항성 신증후군에서 cyclosporine의 반응 효과, 반응 시기, 부작용 및 다른 치료제에 대한 반응을 비교 분석하고자 하였다. 방 법 : 1989년 6월부터 2006년 8월까지 서울아산병원 소아과를 방문한 신증후군 환아 중 초기에 스테로이드 치료에 반응하지 않아 신장 조직 검사 시행 후 cyclosporine을 사용한 22명을 대상으로 cyclosporine의 반응 효과, 반응 시기, 부작용 및 다른 치료제에 대한 반응을 후향적으로 조사하였다. 결 과 : 총 22명중 미세변화형은 12명(54.5%), 국소 분절 사구체 경화증 8명(36.4%), 메산지움 증식 사구체 신염 1명(4.5%), 막성 사구체 신염 1명(4.5%) 이었다. 진단 당시의 평균 연령은 $5.2{\pm}3.3$세이었으며 남녀 비는 1.2:1 이었다. 22명중 15명(68.2%)에서 cyclosporine에 반응하였는데, 이중 미세변화형이었던 환아는 11명(91.7%), 국소 분절 사구체경화증이었던 환아는 3명(37.5%)(미세변화형 vs 국소 분절 사구체경화증, P<0.05), 그리고 막성 사구체 신염 1명이었다. 관해 시기는 cyclosporine 사용 후 $31.5{\pm}15.2$일이었다. Cyclosporine에 반응을 보인 15명 중 4명은 약물 사용 없이 관해 상태이고, 7명은 cyclosporine 사용 중이며, 2명은 cyclosporine 중단 후 스테로이드를 간헐적으로 사용하고 있고, 2명은 cyclosporine과 스테로이드를 함께 투여하고 있다. 이들의 cyclosporine 사용 기간은 각각 $546.5{\pm}346.2$일, $1,392.9{\pm}439.7$일, $439.5{\pm}84.1$일, $433.5{\pm}74.2$일이었다. Cyclosporine 사용 기간 중 혈청 크레아티닌의 변화는 없었으나 신장조직검사를 시행한 8 명중 2 명에서 간질의 섬유화와 세뇨관의 위축이 부분적으로 관찰되었다. 결 론 : 스테로이드 저항성 신증후군에 있어 cyclosporine의 반응은 비교적 좋은 편이고, 특히 미세변화 신증후군에서 그 효과가 높다. 그러나 관해를 유지하기 위해서는 장기간 사용하여야 하는 문제점이 있다.

Purpose : The aim of our study was to evaluate the therapeutic response to cyclosporine, time to remission and side effects in steroid resistant nephrotic syndrome (SRNS). Methods : This study included 22 children with idiopathic SRNS who were treated with cyclosporine between June 1989 and August 2006. Medical records were reviewed retrospectively. Results : The mean age of patients at diagnosis was $5.2{\pm}3.3\;years$. The male to female ratio was 1.2:1. Pre-treatment renal biopsies showed minimal change (MCD) in 12 (54.5%), focal segmental glomerulosclerosis (FSGS) in 8 (36.4%), membranous nephropathy (MGN) in one (4.5%) and mesangioproliferative glomerulonephritis in one (4.5%). 15 (68.2%) patients responded to cyclosporine, of whom 11 (91.6%) patients were MCD, 3 (37.5%) patients FSGS, and 1 patient MGN (MCD vs FSGS, P<0.05). The time to remission in patients who responded to cyclosporine was $31.5{\pm}15.2\;days$. Four of the 15 cyclosporine responders maintained complete remission even after cessation of the medication Seven still received cyclosporine, 2 were intermittently treated with steroids after discontinuation of cyclosporine, and two were treated with cyclosporine and steroids. The mean duration of cyclosporine therapy was $546.5{\pm}346.2$, $1,392.9{\pm}439.7$, $439.5{\pm}84.1$, and $433.5{\pm}74.2$ days, respectively. We performed post-treatment biopsies in 8 patients and partial interstitial fibrosis and tubular atrophy were found in two. Conclusion : The thrapeutic response of cyclosporine is good in steroid resistant nephrotic syndrome, especially in minimal change. But, there is a problem of long term cyclosporine dependency.

키워드

참고문헌

  1. Tarshish P, Tobin IN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: Report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997;8:769-76
  2. Frassinetti Castelo Branco Camurca Fernandes P, Bezerra Da Silvia G Jr, De Sousa Barros FA, Costa Oliveira CM, Kubrusly M, Evangelista JB Jr. Treatment of steroid-resistant nephrotic syndrome with cyclosporine: study of 17 cases and a literature review. J Nephrol 2005;18:711-20
  3. Nammalwar BR, Vijaykumar M, Prahlad N, Jain DV. Steroid resistant nephrotic syndrome is sustained remission attainable. Indian Pediatr 2006;43:39-43
  4. McBryde KD, Kershaw DB, Smoyer WE. Pediatric steroid-resistant nephrotic syndrome. Curr Probl Pediatr Adolesc Health Care 2001;31:280-307 https://doi.org/10.1067/mps.2001.119800
  5. Hamed RM. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. J Nephrol 1997;10:266-70
  6. Meyrier A. Treatment of idiopathic nephrotic syndrome with cyclosporine A. J Nephrol 1997;10:14-24
  7. Hoyer PF, Brodeh J. Initial treatment of idiopathic nephritic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol 2006;17:1151-7 https://doi.org/10.1681/ASN.2005090922
  8. Sohn EK, Cho BS. A clinical trial of cyclosporine A in childhood nephrotic syndrome. Korean J Nephrol 1989;8:306-14
  9. Hong IH, Ko CW, Koo JH, Cho BS, Kim JH, Y ook JW, Kim PK. Long-term Cyclosporine A(Cypol(R)) therapy in children with idiopathic nephrotic syndrome. Korean J Nephrol 2001;20:242-9
  10. Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 1990;4:303-7 https://doi.org/10.1007/BF00862503
  11. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 1995;43:84-8
  12. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978;13:159-65 https://doi.org/10.1038/ki.1978.23
  13. Choi Y, Kang HG, Park JM. Nephrotic syndrome in childhood. Korean J Nephrol 2002;21:356-61
  14. El-Husseini A, El-Basuonv F, Mahmoud I, Sheashaa H, Sabry A, Hassan R et al. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol Dial Transplant 2005;20:2433-8 https://doi.org/10.1093/ndt/gfi059
  15. The primary nephrotic syndrome in children. identification of patients with minimal change nephrotic syndrome frome initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981;98:561-4 https://doi.org/10.1016/S0022-3476(81)80760-3
  16. Cameron JS, Chantler C, Ogg CS, White RH. Long-term stability of remission in nephrotic syndrome after treatment with cyclophosphamide. Br Med J 1974;4:7-11 https://doi.org/10.1136/bmj.4.5935.7
  17. Chiu J, Drummond KN. Long-term follow-up of cyclophosphamide therapy in frequent relapsing minimal lesion nephrotic syndrome. J Pediatr 1974;84:825-30 https://doi.org/10.1016/S0022-3476(74)80757-2
  18. Schulman SL, Kaiser BA, Polinsky MS, Srinivasan R, Baluarte HJ. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 1988;113:996-1001 https://doi.org/10.1016/S0022-3476(88)80570-5
  19. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide dose not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1996;10:590-3 https://doi.org/10.1007/s004670050167
  20. Geary DF, Farine M, Thorner P, Baumal R. Response to cyclophosphamide in steroid-resistant focal segmental glomerulosclerosis: a reappraisal. Clin Nephrol 1984;22:109-13
  21. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003;362:629-39 https://doi.org/10.1016/S0140-6736(03)14184-0
  22. Niaudet P, Habib R. Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 1994;5:1049-56
  23. Lieberman KV, Tejani A, A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996;7:56-63
  24. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S , et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43:1377-84 https://doi.org/10.1038/ki.1993.194
  25. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr 1994;125:981-6 https://doi.org/10.1016/S0022-3476(05)82020-7
  26. Snyder SH, Sabatini DM, Lai MM, Steiner JP, Hamilton GS, Suzdak PD. Neural actions of immunophilin ligands. Trends Pharmacol Sci 1998;19:21-6 https://doi.org/10.1016/S0165-6147(97)01146-2
  27. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38 https://doi.org/10.1056/NEJM198912213212507
  28. Tejani A. Butt K, Trachtman H, Suthanthiran M, Rosen-thal CJ, Khawar MR. Cyclosporine induced remission of relapsing nephrotic syndrome in children. J Pediatr 1987;111:1056-62 https://doi.org/10.1016/S0022-3476(87)80056-2
  29. Kim PK, Kim JH, Chin HJ, Jeong HJ. Therapeutic effect of cyclosporine a on the severe Henoch-Scholein purpura nephritis. J Korean Soc Pediatr Nephrol 1998;2:110-7
  30. Niaudet P, Broyer M. Cyclosporine in the therapy of idiopathic nephrotic syndrome in children. International yearbook of nephrology. Kluwer Academic Publisher 1989:155-68
  31. Klintmalm G, Bohman SO, Sundelin B, Wilczek H. Interstitial fibrosis in renal allografts after 12 to 42 months of cyclosporine treatment: Beneficial effects of low dose in early post transplant period. Lancet 1984;2:950-4
  32. Neild GH, Reuben R, Hartley RB, Cameron JS. Glomerular thrombi in renal allografts associated with cyclosporine treatment. J Clin Pathol 1985;38:253-8 https://doi.org/10.1136/jcp.38.3.253